4-(azepan-1-yl)benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(azepan-1-yl)benzoic acid
• 英文别名: 4-azepan-1-ylbenzoic acid
• 化学式: C₁₃H₁₇NO₂
• 分子量: 219.283
• InChiKey: SBOQUUYPWQTHCF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(azepan-1-yl)benzoic acid 在 lithium hydroxide monohydrate 、 双氧水 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.5h， 生成 (2R)-2-[[3-[[[4-(azepan-1-yl)benzoyl]amino]methyl]-4-propoxyphenyl]methyl]-3-phenylpropanoic acid
  参考文献：
  名称：

  Molecular dynamics study-guided identification of cyclic amine structures as novel hydrophobic tail components of hPPARγ agonists

  摘要：

  We previously reported that a α-benzylphenylpropanoic acid-type hPPARγ-selective agonist with a piperidine ring as the hydrophobic tail part (3) exhibited sub-micromolar-order hPPARγ agonistic activity. In order to enhance the activity, we planned to carry out structural development based on information obtained from the X-ray crystal structure of hPPARγ ligand binding domain (LBD) complexed with 3. However, the shape and/or nature of the binding pocket surrounding the piperidine ring of 3 could not be precisely delineated because the structure of the omega loop of the LBD was poorly defined. Therefore, we constructed and inserted a plausible omega loop by means of molecular dynamics simulation. We then used the reconstructed LBD structure to design new mono-, bi- and tricyclic amine-bearing compounds that might be expected to show greater binding affinity for the LBD. Here, we describe synthesis and evaluation of α-benzylphenylpropanoic acid derivatives 8. As expected, most of the newly synthesized compounds exhibited more potent hPPARγ agonistic activity and greater hPPARγ binding affinity than 3. Some of these compounds also showed comparable aqueous solubility to 3.

  DOI：

  10.1016/j.bmcl.2014.06.023
• 作为产物：
  描述：

  2,2,2,4'-四氟苯乙酮 在 sodium hydroxide 、 三乙胺 作用下， 以 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 生成 4-(azepan-1-yl)benzoic acid
  参考文献：
  名称：

  一种制备 4-氮取代苯甲酸的实用方法

  摘要：

  描述了一种有效且实用的制备 4-氮取代苯甲酸的方法。我们的方法包括 2,2,2,4'-四氟苯乙酮与胺的芳香取代，然后是苯甲酸的卤仿反应。在该方法中，即使对于亲核性较低的 7-、8-和 9-元胺 1 当量。使用时，相应的苯甲酸以中等至极好的收率获得。由于包括纯化在内的实验步骤简单，该方法适用于大规模合成。

  DOI：

  10.1246/cl.2006.1090

文献信息

• Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors Derived from Hexamethylene Amiloride
  作者：Pouria H. Jalily、Jodene Eldstrom、Scott C. Miller、Daniel C. Kwan、Sheldon S. -H. Tai、Doug Chou、Masahiro Niikura、Ian Tietjen、David Fedida

  DOI：10.1124/mol.115.102731

  日期：2016.8

  The increasing prevalence of influenza viruses with resistance to approved antivirals highlights the need for new anti-influenza therapeutics. Here we describe the functional properties of hexamethylene amiloride (HMA)–derived compounds that inhibit the wild-type and adamantane-resistant forms of the influenza A M2 ion channel. For example, 6-(azepan-1-yl)- N -carbamimidoylnicotinamide ( 9 ) inhibits amantadine-sensitive M2 currents with 3- to 6-fold greater potency than amantadine or HMA (IC50 = 0.2 vs. 0.6 and 1.3 µ M, respectively). Compound 9 competes with amantadine for M2 inhibition, and molecular docking simulations suggest that 9 binds at site(s) that overlap with amantadine binding. In addition, tert -butyl 4′-(carbamimidoylcarbamoyl)-2′,3-dinitro-[1,1′-biphenyl]-4-carboxylate ( 27 ) acts both on adamantane-sensitive and a resistant M2 variant encoding a serine to asparagine 31 mutation (S31N) with improved efficacy over amantadine and HMA (IC50 = 0.6 µ M and 4.4 µ M, respectively). Whereas 9 inhibited in vitro replication of influenza virus encoding wild-type M2 (EC50 = 2.3 µ M), both 27 and tert -butyl 4′-(carbamimidoylcarbamoyl)-2′,3-dinitro-[1,1′-biphenyl]-4-carboxylate ( 26 ) preferentially inhibited viruses encoding M2(S31N) (respective EC50 = 18.0 and 1.5 µ M). This finding indicates that HMA derivatives can be designed to inhibit viruses with resistance to amantadine. Our study highlights the potential of HMA derivatives as inhibitors of drug-resistant influenza M2 ion channels.

  对核准抗病毒药物产生耐药性的流感病毒日益增多,这凸显了开发新型抗流感药物的必要性。本文描述了六亚甲基氨氯吡嗪(HMA)衍生物的功能特性,它们能抑制A型流感M2离子通道的野生型和金刚烷胺耐药型。例如, 6-( 唑戊吡嗪-1-吡啦达)-N-甲甲喷达吡嗪-氨酸胺(9)对金刚烷胺敏感的M2离子通道电流的抑制效力比金刚烷胺或HMA高3至6倍(IC50分别为0.2、0.6和1.3μM)。化合物9与金刚烷胺竞争抑制M2, 分子对接模拟显示9结合在金刚烷胺结合位点的重叠处。此外, 二（伞形酮基羰基）-2',3-二硝基-[1,1'-苄基]-4-羧酸替丁酯(27)既对敏感型M2有效, 也对编码丝氨酸31突变为天冬酰胺(S31N)的耐药型M2变种有效, 且效力优于金刚烷胺和HMA(IC50分别为0.6μM和4.4μM)。虽然9抑制了编码野生型M2的流感病毒的体外复制(EC50=2.3μM), 但27和二（伞形酮基羰基）-2',3-二硝基-[1,1'-苄基]-4-羧酸替丁酯(26)更倾向于抑制编码M2(S31N)的病毒(各自的EC50分别为18.0和1.5μM)。这一发现表明,可以设计HMA衍生物来抑制金刚烷胺耐药的病毒。我们的研究强调了HMA衍生物作为耐药性流感M2离子通道抑制剂的潜力。
• A Practical Method for the Preparation of 4-Nitrogen-substituted Benzoic Acids
  作者：Tsuyoshi Shinozuka、Akira Nakao、Keiji Saito、Satoru Naito

  DOI：10.1246/cl.2006.1090

  日期：2006.10

  efficient and practical method for the preparation of 4-nitrogen-substituted benzoic acids is described. Our method consists of the aromatic substitution of 2,2,2,4'-tetrafluoroacetophenone with amines, followed by haloform reaction to the benzoic acids. In this method, even though for the less nucleophilic 7-, 8-, and 9-membered amines 1 equiv. was used, corresponding benzoic acids were obtained in moderate

  描述了一种有效且实用的制备 4-氮取代苯甲酸的方法。我们的方法包括 2,2,2,4'-四氟苯乙酮与胺的芳香取代，然后是苯甲酸的卤仿反应。在该方法中，即使对于亲核性较低的 7-、8-和 9-元胺 1 当量。使用时，相应的苯甲酸以中等至极好的收率获得。由于包括纯化在内的实验步骤简单，该方法适用于大规模合成。
• NOVEL ONIUM SALT COMPOUND, RESIST COMPOSITION, AND PATTERN FORMING PROCESS
  申请人：Shin-Etsu Chemical Co., Ltd.

  公开号：US20160131972A1

  公开（公告）日：2016-05-12

  Sulfonium and iodonium salts of a carboxylate having an aromatic ring to which a nitrogen-containing alkyl or cyclic structure is attached are novel. The onium salt functions as an acid diffusion controlling agent in a resist composition, enabling to form a pattern of good profile with high resolution, improved MEF, LWR and DOF.

  一种具有芳香环的羧酸酯的砜和碘化物盐，其中连接有含氮烷基或环状结构，是一种新颖的化合物。该砜盐在抗蚀组合物中作为酸扩散控制剂，有助于形成具有高分辨率、改善MEF、LWR和DOF的良好轮廓图案。
• Piperazine derivatives as MAGL inhibitors
  申请人：Hoffmann-La Roche Inc.

  公开号：US11390610B2

  公开（公告）日：2022-07-19

  The invention provides new heterocyclic compounds having the general Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X, Y1 and Y2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

  本发明提供了具有通式（I）的新杂环化合物或其药学上可接受的盐、 其中 R1、R2、X、Y1 和 Y2 如本文所述。
• Development of second generation EP2 antagonists with high selectivity
  作者：Thota Ganesh、Jianxiong Jiang、Ray Dingledine

  DOI：10.1016/j.ejmech.2014.05.076

  日期：2014.7

  EP2 receptor has emerged as an important biological target for therapeutic intervention. In particular, it has been shown to exacerbate disease progression of a variety of CNS and peripheral diseases. Deletion of the EP2 receptor in mouse models recapitulates several features of the COX-2 inhibition, thus presenting a new avenue for anti-inflammatory therapy which could bypass some of the adverse side effects observed by the COX-2 inhibition therapy. We have recently reported a cinnamic amide class of EP2 antagonists with high potency, but these compounds exhibited a moderate selectivity against prostanoid receptor DP1. Moreover they possess acrylamide moiety in the structure, which may result in liver toxicity over longer period of use in a chronic disease model. Thus, we now developed a second generation compounds that devoid of the acrylamide functionality and possess high potency and improved (>1000-fold) selectivity to EP2 over other prostanoid receptors. (C) 2014 Elsevier Masson SAS. All rights reserved.